RxDoctor Payments Data

Tiffany Shaughnessy

Psychiatric/Mental Health · Syracuse, NYNPI 1952980518

Payments from drug & device makers

$2,791in general payments, 2019–2025

Across 88 payments — averaging $31.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$729
  • AbbVie$684
  • Alkermes, Inc.$267
  • Neurocrine Biosciences, Inc.$186
  • Otsuka America Pharmaceutical, Inc.$175
  • Sunovion Pharmaceuticals Inc.$173
  • plus $577 from 7 others

What the payments were for

  • Food & beverage$2,791100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,791 in reported general payments places this provider in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

See all psychiatric/mental health providers in New York

Medicare billing

Part B allowed, 2024
$14,970
Medicare patients
17
Services billed
184

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate19$62,694
VraylarCariprazine Hcl18$47,458
Chlorpromazine Hcl12$5,381
Atomoxetine Hcl33$2,527
Clozapine28$2,284
Fluoxetine Hcl43$2,183
Aripiprazole103$1,743
Bupropion XlBupropion Hcl61$1,568
Duloxetine Hcl42$1,339
Prazosin Hcl27$1,313
Quetiapine Fumarate59$1,262
Lurasidone Hcl15$1,130
Benztropine Mesylate87$900
Divalproex Sodium ErDivalproex Sodium15$849
Trazodone Hcl82$844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$165$62,69419 claims
AbbVieVraylar$684$47,45818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,385 psychiatric/mental health providers in New York.

Other psychiatric/mental health in Syracuse

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →